Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Canter, N. L.
Right arrow Articles by Growdon, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canter, N. L.
Right arrow Articles by Growdon, J. H.
NEUROLOGY 1982;32:1260
© 1982 American Academy of Neurology

Lecithin does not affect EEG spectral analysis or P300in Alzheimer disease

Nancy L. Canter, Mark Hallett and John H. Growdon

Section of Neurology (Dr. Hallett), Department of Medicine, Brigham and Women's Hospital and Department of Neurology, Harvard Medical School, the Department of Neurology (Dr. Growdon), New England Medical Center Hospital and Tufts University School of Medicine, Boston, and Wellesley College (Ms. Canter) Wellesley, MA.

We studied 10 patients with Alzheimer disease by measuring EEG compressed spectral analysis and the P300 latency and topography before and after 2 weeks of lecithin therapy. There was a significant positive correlation between the degree of dementia measured by the Blessed Dementia Scale and the amount of EEG delta activity. The P300 latency was related to the ability to detect the rare tones in the P300 paradigm. Lecithin therapy increased mean plasma choline levels but did not affect EEG power or the P300 latency or topography.

Address correspondence and reprint requests to Dr. Hallett, Section of Neurology, Brigham and Women's Hospital, Boston, MA 02115.

Accepted for publication March 30, 1982.




This article has been cited by other articles:


Home page
J PsychopharmacolHome page
N.H.P. Allen and A. Burns
The treatment of Alzheimer's disease
J Psychopharmacol, January 1, 1995; 9(1): 43 - 56.
[PDF]


Home page
Arch NeurolHome page
W. J. Estrin, S. A. Cavalieri, P. Wald, C. E. Becker, J. R. Jones, and J. E. Cone
Evidence of Neurologic Dysfunction Related to Long-term Ethylene Oxide Exposure
Arch Neurol, December 1, 1987; 44(12): 1283 - 1286.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by AAN Enterprises, Inc.